Context Therapeutics Reports Full Year 2025 Operating And Financial Results

📅 23/03/2026 16:20 📰 menafn 👁️ 16 lectures 🌍 États-Unis 📂 Science

(MENAFN - GlobeNewsWire - Nasdaq) Phase 1a interim data for ongoing trial of CTIM-76 (CLDN6 x CD3) expected in June 2026 Phase 1a interim data for ongoing trial of CT-95 (MSLN x CD3) expected in ...